logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 12714692 B1

PDFFull Text
Date of Patent:
Aug. 25, 2026

Filed:

Apr. 26, 2023

Bacterial dna gyrase inhibitors and methods of use thereof

Applicants:

The Florida International University Board of Trustees, Miami, FL (US);

University of Central Florida Research Foundation, Inc., Orlando, FL (US);

Inventors:

Fenfei Leng, Palmetto Bay, FL (US);

Eddy Alfonso, Miami, FL (US);

Zifang Deng, Miami, FL (US);

Adel Nefzi, Miami, FL (US);

Kyle Rohde, Orlando, FL (US);

Assignees:

THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES, Miami, FL (US);

UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC., Orlando, FL (US);

Attorney:

SALIWANCHIK, LLOYD & EISENSCHENK

Primary Examiner:

Lauren Wells

Int. Cl.
CPC ...
A61K 31/381 (2006.01); A61K 31/122 (2006.01); A61K 31/136 (2006.01); A61K 31/137 (2006.01); A61K 31/15 (2006.01); A61K 31/164 (2006.01); A61K 31/192 (2006.01); A61K 31/195 (2006.01); A61K 31/196 (2006.01); A61K 31/197 (2006.01); A61K 31/24 (2006.01); A61K 31/345 (2006.01); A61K 31/351 (2006.01); A61K 31/352 (2006.01); A61K 31/357 (2006.01); A61K 31/365 (2006.01); A61K 31/366 (2006.01); A61K 31/404 (2006.01); A61K 31/41 (2006.01); A61K 31/4155 (2006.01); A61K 31/4162 (2006.01); A61K 31/4178 (2006.01); A61K 31/4184 (2006.01); A61K 31/422 (2006.01); A61K 31/4245 (2006.01); A61K 31/426 (2006.01); A61K 31/427 (2006.01); A61K 31/428 (2006.01); A61K 31/429 (2006.01); A61K 31/433 (2006.01); A61K 31/436 (2006.01); A61K 31/4365 (2006.01); A61K 31/437 (2006.01); A61K 31/438 (2006.01); A61K 31/4402 (2006.01); A61K 31/443 (2006.01); A61K 31/4436 (2006.01); A61K 31/4439 (2006.01); A61K 31/45 (2006.01); A61K 31/47 (2006.01); A61K 31/473 (2006.01); A61K 31/4745 (2006.01); A61K 31/48 (2006.01); A61K 31/496 (2006.01); A61K 31/498 (2006.01); A61K 31/502 (2006.01); A61K 31/513 (2006.01); A61K 31/515 (2006.01); A61K 31/517 (2006.01); A61K 31/519 (2006.01); A61K 31/53 (2006.01); A61K 31/5377 (2006.01); A61K 31/538 (2006.01); A61K 31/635 (2006.01); A61K 31/7076 (2006.01); A61P 31/04 (2006.01);
U.S. Cl.
CPC ...
A61K 31/404 (2013.01); A61K 31/122 (2013.01); A61K 31/136 (2013.01); A61K 31/137 (2013.01); A61K 31/15 (2013.01); A61K 31/164 (2013.01); A61K 31/192 (2013.01); A61K 31/195 (2013.01); A61K 31/196 (2013.01); A61K 31/197 (2013.01); A61K 31/24 (2013.01); A61K 31/345 (2013.01); A61K 31/351 (2013.01); A61K 31/352 (2013.01); A61K 31/357 (2013.01); A61K 31/365 (2013.01); A61K 31/366 (2013.01); A61K 31/381 (2013.01); A61K 31/41 (2013.01); A61K 31/4155 (2013.01); A61K 31/4162 (2013.01); A61K 31/4178 (2013.01); A61K 31/4184 (2013.01); A61K 31/422 (2013.01); A61K 31/4245 (2013.01); A61K 31/426 (2013.01); A61K 31/427 (2013.01); A61K 31/428 (2013.01); A61K 31/429 (2013.01); A61K 31/433 (2013.01); A61K 31/436 (2013.01); A61K 31/4365 (2013.01); A61K 31/437 (2013.01); A61K 31/438 (2013.01); A61K 31/4402 (2013.01); A61K 31/443 (2013.01); A61K 31/4436 (2013.01); A61K 31/4439 (2013.01); A61K 31/45 (2013.01); A61K 31/47 (2013.01); A61K 31/473 (2013.01); A61K 31/4745 (2013.01); A61K 31/48 (2013.01); A61K 31/496 (2013.01); A61K 31/498 (2013.01); A61K 31/502 (2013.01); A61K 31/513 (2013.01); A61K 31/515 (2013.01); A61K 31/517 (2013.01); A61K 31/519 (2013.01); A61K 31/53 (2013.01); A61K 31/5377 (2013.01); A61K 31/538 (2013.01); A61K 31/635 (2013.01); A61K 31/7076 (2013.01); A61P 31/04 (2018.01);
Abstract

The subject invention provides fluorophore-quencher nucleic acid molecules comprising relaxed or supercoiled DNA molecules, and their use in rapid and efficient high-throughput screening (HTS) assays to screen and identify compounds that inhibit DNA gyrases. These compounds can be used as antibiotics for treating bacterial infections, especially, multidrug resistant bacterial infections.

Find Patent Forward Citations

Loading…